Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etoposide capsules + bevacizumab + avelumab for platinum‑resistant/refractory ovarian cancer (Phase II, single‑arm)
ChiCTR2500111824Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etoposide, bevacizumab and avelumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Progression-free survival. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
etoposidebevacizumabavelumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2500111824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111824.